Product
Nicotinic acid
Aliases
Niacin
Name
Niacin
INN Name
Niacin
FDA Approved
Yes
5 clinical trials
9 organizations
10 indications
3 documents
Indication
HypercholesterolemiaIndication
Safety IssuesIndication
PharmacokineticsIndication
Type 2 Diabetes MellitusIndication
Glucose Metabolism DisordersIndication
Blood sugarIndication
HypertensionIndication
Diabetes MellitusIndication
Type 2Indication
Type 2 DiabetesClinical trial
A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial HypercholesterolemiaStatus: Completed, Estimated PCD: 2021-01-14
Clinical trial
A Phase I, Double-blind, Randomised, Placebo-controlled, Single-ascending and Multiple-ascending Dose Trial to Evaluate the Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With PrediabetesStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Regulation of Endogenous Glucose Production by Central KATP ChannelsStatus: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant RecipientsStatus: Withdrawn, Estimated PCD: 2023-04-21
Clinical trial
Quantifying Brown Adipose Tissue Thermogenesis in Type 2 DiabetesStatus: Recruiting, Estimated PCD: 2024-12-01
Organization
Macleods Pharmaceuticals LimitedOrganization
Aurobindo Pharma LimitedDocument
DailyMed Label: NiacinOrganization
Emerald Therapeutics, LLCOrganization
Chartwell RX, LLCOrganization
Lannett Company, Inc.Organization
Amneal Pharmaceuticals LLCDocument
DailyMed Label: NiaspanOrganization
Rebel Distributors Corp.Organization
Sun Pharmaceutical Industries, Inc.Document
DailyMed Label: NiacorOrganization
Avondale Pharmaceuticals, LLC